Astellas Pharma said it has submitted its anti-clotting drug YM150 for Japanese government approval. The drug is a factor Xa inhibitor used to prevent blood clots in those who had knee replacement surgery.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||